Peptide | Denomination | Start position | Sequence | Score* | FI† |
---|
No.1 | Sp1 | 2 | FIFLLFLTL | 24 | 0.5 |
No.2 | Sp2 | 851 | MIAAYTAAL | 26 | 0.8 |
No.3 | Sp3 | 404 | VIADYNYKL | 26 | 0.4 |
No.4 | Sp4 | 208 | DLPSGFNTL | 24 | 0.1 |
No.5 | Sp5 | 940 | ALNTLVKQL | 27 | 1.1 |
No.6 | Sp6 | 1174 | NLNESLIDL | 27 | 1.1 |
No.7 | Sp7 | 673 | SIVAYTMSL | 25 | 1.2 |
No.8 | Sp8 | 958 | VLNDILSRL | 27 | 1.5 |
- * HLA-A*0201-binding motif score from algorithm SYFPEITHI ≥ 24. The eight peptides were also predicted and selected using ProPred1, in which the threshold of HLA-A2-binding motif is 4% and the threshold of proteasomal and immunoproteasomal cleavage site is 8%.
- † Increase of HLA-A*0201 molecules on T2 cell surface. FI = [(mean FITC fluorescence with the given peptide - mean FITC fluorescence without peptide)/(mean FITC fluorescence without peptide)]. FI > 1.0 indicates high-affinity peptides; FI ≤ 1.0, low-affinity peptides. HLA-A*0201-restricted peptide S411-420 was used as a positive control for HLA-A*0201-binding ability, while the H-2b-restricted peptide HBcAg(131-140) was used as a negative control.